HomeCompareJCRRF vs GBDC

JCRRF vs GBDC: Dividend Comparison 2026

JCRRF yields 3.22% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JCRRF wins by $569.55M in total portfolio value· pulled ahead in Year 7
10 years
JCRRF
JCRRF
● Live price
3.22%
Share price
$4.17
Annual div
$0.13
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$590.33M
Annual income
$557,098,169.44
Full JCRRF calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — JCRRF vs GBDC

📍 JCRRF pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJCRRFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JCRRF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JCRRF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JCRRF
Annual income on $10K today (after 15% tax)
$273.77/yr
After 10yr DRIP, annual income (after tax)
$473,533,444.02/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, JCRRF beats the other by $459,602,570.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JCRRF + GBDC for your $10,000?

JCRRF: 50%GBDC: 50%
100% GBDC50/50100% JCRRF
Portfolio after 10yr
$305.55M
Annual income
$286,743,716.42/yr
Blended yield
93.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

JCRRF
No analyst data
Altman Z
1.4
Piotroski
4/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JCRRF buys
0
GBDC buys
2
PoliticianChamberTickerTypeAmountDate
David P. Joyce🏢 House$GBDC▼ Sell$1,001 - $15,0002023-06-30
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002023-06-19
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002022-07-14
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002022-07-12
Teresa Leger Fernandez🏢 House$GBDC▼ Sell$15,001 - $50,0002021-01-20
David P. Joyce🏢 House$GBDC▲ Buy$1,001 - $15,0002020-02-25
David P. Joyce🏢 House$GBDC▲ Buy$15,001 - $50,0002019-05-30
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJCRRFGBDC
Forward yield3.22%11.85%
Annual dividend / share$0.13$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%51.1%
Portfolio after 10y$590.33M$20.78M
Annual income after 10y$557,098,169.44$16,389,263.41
Total dividends collected$587.89M$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: JCRRF vs GBDC ($10,000, DRIP)

YearJCRRF PortfolioJCRRF Income/yrGBDC PortfolioGBDC Income/yrGap
1$11,344$644.17$12,490$1,790.28$1.1KGBDC
2$13,504$1,365.91$16,522$3,157.73$3.0KGBDC
3$17,489$3,039.22$23,578$5,898.68$6.1KGBDC
4$26,070$7,356.96$37,115$11,886.75$11.0KGBDC
5$48,393$20,498.67$66,136$26,423.57$17.7KGBDC
6$122,906$71,124.57$137,257$66,491.44$14.4KGBDC
7← crossover$469,147$337,637.75$341,734$194,868.54+$127.4KJCRRF
8$2,910,974$2,408,986.96$1,050,788$685,133.02+$1.86MJCRRF
9$31,053,709$27,938,966.99$4,099,314$2,974,971.01+$26.95MJCRRF
10$590,325,638$557,098,169.44$20,775,530$16,389,263.41+$569.55MJCRRF

JCRRF vs GBDC: Complete Analysis 2026

JCRRFStock

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

Full JCRRF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this JCRRF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JCRRF vs SCHDJCRRF vs JEPIJCRRF vs OJCRRF vs KOJCRRF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.